Assessment of Momordica charantia and Gymnema sylvestre's Anti-Diabetic Potential in Streptozotocin-Induced Diabetic Rats.

Introduction: Hyperglycemia due to insulin resistance or decreased insulin production characterizes diabetes mellitus, a chronic metabolic condition. Due to its promise in managing diabetes with fewer adverse effects, herbal treatments have received interest. The anti-diabetic effects of Gymnema sylvestre and Momordica charantia have long made them popular medicinal herbs. Their effectiveness in rats with diabetes caused by streptozotocin (STZ) is the focus of this investigation. Materials and Methods: The use of streptozotocin (50 mg/kg, intraperitoneally) was used to produce diabetes in Wistar rats. Rats were randomly assigned to one of five groups: normal control, diabetic control, G. sylvestre (250 mg/kg), M. charantia (250 mg/kg), or combination (250 mg/kg each extract). In this four-week trial, researchers looked at participants' oxidative stress markers, body weight, lipid profiles, and fasting blood glucose (FBG) levels. Additionally, pancreatic tissue was examined histopathologically. Results: G. sylvestre and M. charantia both considerably decreased FBG levels when contrasted with the diabetic control group (p < 0.05). The hypoglycemic impact was particularly noticeable in the combo treatment. Lipid profile indicators, such as total cholesterol and triglycerides, improved in the treated groups. The levels of antioxidant enzymes (SOD, CAT, and GSH) were found to be significantly higher, and histological analysis showed that the treated groups had regenerated pancreatic β-cells. Conclusion: According to the results, both Momordica charantia and Gymnema sylvestre have strong anti-diabetic effects, but the combination is even more effective. Possible supplementary use of these herbal extracts in the treatment of diabetes is being considered. To confirm their medicinal efficacy, additional clinical trials are necessary. [ABSTRACT FROM AUTHOR]